Clinical trial
A PHASE 2 CLINICAL STUDY OF POMALIDOMIDE (CC-4047) MONOTHERAPY FOR CHILDREN AND YOUNG ADULTS WITH RECURRENT OR PROGRESSIVE PRIMARY BRAIN TUMORS
NCT03257631 is registered in ClinicalTrials.gov with Celgene as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A PHASE 2 CLINICAL STUDY OF POMALIDOMIDE (CC-4047) MONOTHERAPY FOR CHILDREN AND YOUNG ADULTS WITH RECURRENT OR PROGRESSIVE PRIMARY BRAIN TUMORS
- Lead sponsor
- Celgene
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- September 18, 2017
- Completion date
- September 14, 2023
- Enrollment
- 53 (actual)
- Sites
- 22
Conditions
As the registry lists them; a condition with its own page is linked.